MD Anderson Cancer Center Offers an Essential 6-Day Course: Mastering Hematology & Oncology for ABIM Success
MD Anderson Cancer Center shared an inviting post on X:
”A virtual live-streaming course will offer comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.”
To learn more and register, follow the link.
A 6-day virtual course by MD Anderson Cancer Center and Baylor College of Medicine offers a comprehensive review of current practices in managing blood disorders and malignancies, tailored to help participants prepare for the ABIM certification in Hematology and Medical Oncology.
The program covers key updates in pharmacology, molecular genetics, risk assessment, and radiation oncology.
By the end of the course, participants will be equipped to:
- Confidently prepare for hematology and medical oncology subspecialty and recertification exams.
- Apply up-to-date standards of care in treating cancer, blood disorders, and malignancies.
- Demonstrate comprehensive knowledge in hematology and medical oncology.
- Integrate recent advances into the management of hematologic and oncologic patients.
Don’t miss your chance, apply now!
Stay informed on the latest conferences, courses, and webinars—read Hemostasis Today for all the updates!
-
Nov 4, 2025, 09:26Courtney Lawrence: One of Our Most Popular American Red Cross SUCCESS Talks is Just Around the Corner!
-
Nov 4, 2025, 09:21New Study by Emmanuel J Favaloro and Team Questions Consistency in APS Classification and Diagnosis
-
Nov 4, 2025, 09:20Yazan Abou Ismail to Present Insights on AI Models in TTP at 67th ASH Annual Meeting
-
Nov 4, 2025, 09:17David Calvet Canut on Takeda's HyHub: A Shift Toward Patient-Centered Biologics
-
Nov 4, 2025, 09:16Samantha Nelson Encourages You to Share Your Experience on World Thrombosis Day
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!